Grünenthal Reports Strong 2024 Financial Results

Grünenthal GmbH has announced robust financial results for 2024, driven by strategic growth and the acquisition of Valinor Pharma in the US. Despite challenges from PalexiaTM's loss of exclusivity, the company maintained steady revenues of €1.8 billion and an adjusted EBITDA of €412 million. This reflects Grünenthal's resilience and effective cost management, leading to a 13% increase in operating cash flow, totaling €212 million.

The acquisition of Valinor Pharma has significantly bolstered Grünenthal's portfolio, enhancing its US presence, now the second-largest affiliate globally. Additionally, efficiency improvements in Europe and Latin America contributed to a better cost profile. Grünenthal ended the year with a strong financial base, including the issuance of a €500 million bond, to support future R&D and strategic acquisitions.

Key advancements in R&D continue, focusing on the GRM and NOP programs and prioritizing growth in QutenzaTM and Established Brands while further integrating Valinor Pharma. Grünenthal remains committed to ESG initiatives, securing recognition from MSCI and Sustainalytics.